Objective To report the method and outcomes ot arthroscopic examination and removal of the.loose bodies from the posterior compartments of the knee. Methods Four mm 30? arthroscope was used to examine the patients with osteoarthritic loose body in the politeal fossa on the preoperative roentgenograms via posterolateral and posteromedial portals. An assistant portal at 1 - 1.5 cm in front of the standard portals was made, and loose bodies were removed arthroscopically. Postoperative algesia on the leg and foot, active flexion and extension of the malleolus, toe and phalanxes, and the lateral stress test of the knee were observed. Results Of the three hundred and sixty-four cases undergone knee arthroscopy during January 1999 to December 2000, 17 case had osteoarthritis and loose bodies in the posterior compartment on the roentgenograms. Loose bodies were found in the posterolateral portal in 9 cases, which were removed arthroscopically. Howerver, no loose body was found via the posteromedial portal. The mean duration of follow-up was 14. 88 months. Except one case with subcutaneous loose body was overlooked and one patient developed hematoma, there was no neurovascular or ligamentous complications. Conclusion It is safe and possible to use 4 mm 30? arthroscope to examine the posterior compartments of the knee and to remove loose bodies.

Elevated fibroblast growth factor 23 (FGF23) in X-linked hypophosphatemia (XLH) results in rickets and phosphate wasting, manifesting by severe bone and dental abnormalities. Burosumab, a FGF23-neutralizing antibody, an alternative to conventional treatment (phosphorus and active vitamin D analogs), showed significant improvement in the long bone phenotype. Here, we examined whether FGF23 antibody (FGF23-mAb) also improved the dentoalveolar features associated with XLH. Four-week-old male Hyp mice were injected weekly with 4 or 16 mg·kg^-1 of FGF23-mAb for 2 months and compared to wild-type (WT) and vehicle (PBS) treated Hyp mice (n = 3-7 mice). Micro-CT analyses showed that both doses of FGF23-mAb restored dentin/cementum volume and corrected the enlarged pulp volume in Hyp mice, the higher concentration resulting in a rescue similar to WT levels. FGF23-mAb treatment also improved alveolar bone volume fraction and mineral density compared to vehicle-treated ones. Histology revealed improved mineralization of the dentoalveolar tissues, with a decreased amount of osteoid, predentin and cementoid. Better periodontal ligament attachment was also observed, evidenced by restoration of the acellular cementum. These preclinical data were consistent with the retrospective analysis of two patients with XLH showing that burosumab treatment improved oral features. Taken together, our data show that the dentoalveolar tissues are greatly improved by FGF23-mAb treatment, heralding its benefit in clinics for dental abnormalities.
Humans ; Male ; Mice ; Animals ; Familial Hypophosphatemic Rickets/pathology* ; Fibroblast Growth Factor-23 ; Retrospective Studies ; Fibroblast Growth Factors/metabolism* ; Bone and Bones/metabolism* ; Phosphates/therapeutic use*